Alopecia Areata After Mogamulizumab Treatment

A 42-year-old woman with Sézary syndrome developed alopecia areata universalis after 16 months of mogamulizumab treatment, which initially led to disease remission. She experienced total body hair loss but achieved full regrowth after 13 months of treatment with intralesional triamcinolone and topical clobetasol. This case suggests that mogamulizumab-induced AA may result from the depletion of regulatory T cells, disrupting immune homeostasis and leading to autoimmunity. Further studies are needed to understand the mechanistic basis and prognostic significance of mogamulizumab-associated AA.